0
-
An empty cart
You have no item in your shopping cart
Investors in Tyme Technologies(Nasdaq: TYME), a clinical-stage biotech company focused on cancer, should be excited for the near-term future in my humble estimation as I believe shares of this $2 stock could spike it to $8 in the coming weeks/months. SM-88: A Nightmare For Pancreatic Cancer Cells The company’s big headline has been on one […]